Were Analysts Bearish AbbVie Inc. (NYSE:ABBV) This Week?

AbbVie Inc. (NYSE:ABBV) Logo
Investors sentiment decreased to 0.82 in Q3 2018. Its down 0.12, from 0.94 in 2018Q2. It worsened, as 60 investors sold AbbVie Inc. shares while 637 reduced holdings. 107 funds opened positions while 466 raised stakes. 994.12 million shares or 0.91% less from 1.00 billion shares in 2018Q2 were reported.
Kentucky Retirement Sys reported 0.51% in AbbVie Inc. (NYSE:ABBV). Arete Wealth Advsr Limited Com owns 13,618 shares or 0.29% of their US portfolio. B Riley Wealth Mgmt Inc, a Tennessee-based fund reported 7,774 shares. Great West Life Assurance Com Can reported 0.3% stake. Raymond James, Florida-based fund reported 3.54M shares. Los Angeles Mgmt And Equity Research owns 634,252 shares or 0.31% of their US portfolio. Veritas Invest Mgmt Llp holds 0.01% in AbbVie Inc. (NYSE:ABBV) or 1,400 shares. Halsey Assocs Ct stated it has 14,393 shares. Campbell Newman Asset holds 25,548 shares. Sfe Investment Counsel invested in 76,826 shares or 2.8% of the stock. Carret Asset Limited Liability Company invested in 0.99% or 68,185 shares. Chesley Taft Assoc Ltd Liability Co owns 60,140 shares or 0.45% of their US portfolio. Camarda Advsr Lc, Florida-based fund reported 449 shares. Sumitomo Mitsui Asset Management Commerce Ltd has 0.2% invested in AbbVie Inc. (NYSE:ABBV) for 137,314 shares. Jacobs & Ca stated it has 71,753 shares.

Since August 17, 2018, it had 0 insider buys, and 6 selling transactions for $26.66 million activity. 42,450 shares were sold by Gosebruch Henry O, worth $3.82 million. CHASE WILLIAM J also sold $5.40M worth of AbbVie Inc. (NYSE:ABBV) shares. $1.50 million worth of AbbVie Inc. (NYSE:ABBV) was sold by GONZALEZ RICHARD A. On Friday, August 17 the insider SEVERINO MICHAEL sold $4.88M.

AbbVie Inc. (NYSE:ABBV) Ratings Coverage

Among 4 analysts covering AbbVie (NYSE:ABBV), 2 have Buy rating, 1 Sell and 1 Hold. Therefore 50% are positive. AbbVie had 7 analyst reports since July 30, 2018 according to SRatingsIntel. The firm has “Buy” rating by Bank of America given on Wednesday, August 22. The firm earned “Neutral” rating on Thursday, January 3 by Bank of America. The company was maintained on Monday, November 5 by BMO Capital Markets. The rating was maintained by Bank of America with “Buy” on Thursday, October 4. The stock of AbbVie Inc. (NYSE:ABBV) earned “Buy” rating by Argus Research on Tuesday, November 6. Bank of America maintained AbbVie Inc. (NYSE:ABBV) on Monday, July 30 with “Buy” rating. Below is a list of AbbVie Inc. (NYSE:ABBV) latest ratings and price target changes.

03/01/2019 Broker: Bank of America Old Rating: Buy New Rating: Neutral Downgrade
26/12/2018 Broker: Standpoint Research Rating: Buy Initiates Coverage On
06/11/2018 Broker: Argus Research Old Rating: Buy New Rating: Buy Old Target: $130 New Target: $115 Maintain
05/11/2018 Broker: BMO Capital Markets Old Rating: Underperform New Rating: Underperform Old Target: $78 New Target: $71 Maintain
04/10/2018 Broker: Bank of America Old Rating: Buy New Rating: Buy Old Target: $107 New Target: $106 Maintain
22/08/2018 Broker: Bank of America Old Rating: Buy New Rating: Buy Old Target: $105 New Target: $107 Maintain
30/07/2018 Broker: Bank of America Old Rating: Buy New Rating: Buy Old Target: $112 New Target: $105 Maintain

The stock decreased 2.23% or $1.95 during the last trading session, reaching $85.29. About 1.96 million shares traded. AbbVie Inc. (NYSE:ABBV) has declined 7.04% since January 14, 2018 and is downtrending. It has underperformed by 7.04% the S&P500.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company has market cap of $128.30 billion. The firm offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It has a 17.81 P/E ratio. It also provides Kaletra, an anti- human immunodeficiency virus-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants.

AbbVie Inc. (NYSE:ABBV) Ratings Chart

(adsbygoogle = window.adsbygoogle || []).push({});

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.